BEXIMCO PHARMA.GDR REGS 1 (R2WA) — Net Asset Momentum
BEXIMCO PHARMA.GDR REGS 1 (R2WA) recorded a net asset momentum of 9.0% as of June 2024, with net assets of €51.90 Billion EUR. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See R2WA net assets for net asset value and shareholders' equity analysis.
YoY Momentum
Current Net Assets
Years of Data
Country
BEXIMCO PHARMA.GDR REGS 1 Net Asset Momentum (2021–2024)
This chart tracks BEXIMCO PHARMA.GDR REGS 1's year-over-year net asset growth across 4 annual reporting periods from 2021 to 2024. The most recent momentum reading is +9.0%, with net assets of €51.90 Billion EUR as of June 2024. For live market cap and overall valuation, see BEXIMCO PHARMA.GDR REGS 1 (R2WA) market capitalisation.
Annual Net Asset History for BEXIMCO PHARMA.GDR REGS 1 (2021–2024)
The table below shows the complete annual net asset history for BEXIMCO PHARMA.GDR REGS 1 from 2021 to 2024, covering 4 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. Check tangible net worth ratio of BEXIMCO PHARMA.GDR REGS 1 to evaluate the tangible quality of the company's equity base.
| Year | Net Assets (EUR) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2024 | €51.90 Billion | €69.34 Billion | €17.44 Billion | ▲ +9.0% |
| 2023 | €47.62 Billion | €69.16 Billion | €21.54 Billion | ▲ +6.7% |
| 2022 | €44.64 Billion | €66.15 Billion | €21.51 Billion | ▲ +19.5% |
| 2021 | €37.36 Billion | €52.25 Billion | €14.88 Billion | — |